 The safety of the combination of erlotinib with AT-101 has not been assessed. It is therefore proposed that a phase I study be performed using standard FDA approved dose of erlotinib 150 mgday with an effective dose of AT-101 40 mg twice daily for 3 days of a 3 week cycle. 